24
Participants
Start Date
March 1, 2019
Primary Completion Date
May 30, 2019
Study Completion Date
May 30, 2019
SY-009
The study will be initiated in healthy subjects at a 0.5mg dose that is the maximum recommended starting dose(MRSD) . Doses will be escalated in subsequent dosing process, after appropriate review of safety data. The subsequent planned doses are 2,5, 10, 20, 40mg successively. The increment of the dose escalation may be reduced, a lower dose may be administered following data review.
China-Japan Friendship Hospital, Beijing
Suzhou Yabao Pharmaceutical R&D Co., Ltd.
INDUSTRY